In vitro and in vivo pre-clinical analysis of a F(ab')2 fragment of panitumumab for molecular imaging and therapy of HER1-positive cancers

[1]  T. Nayak,et al.  HER1-Targeted 86Y-Panitumumab Possesses Superior Targeting Characteristics than 86Y-Cetuximab for PET Imaging of Human Malignant Mesothelioma Tumors Xenografts , 2011, PloS one.

[2]  M. Brechbiel,et al.  Improved speciation characteristics of PEGylated indocyanine green-labeled Panitumumab: revisiting the solution and spectroscopic properties of a near-infrared emitting anti-HER1 antibody for optical imaging of cancer. , 2010, Bioconjugate chemistry.

[3]  Xiaoyuan Chen,et al.  Molecular Cancer apeutics linical Development ermal Growth Factor Receptor – Targeted ioimmunotherapy of Human Head and Neck Cancer ografts Using 90 Y-Labeled Fully Human Ther ibody Panitumumab , 2010 .

[4]  A. Wu,et al.  Positive progress in immunoPET--not just a coincidence. , 2010, Cancer biotherapy & radiopharmaceuticals.

[5]  T. Nayak,et al.  Preparation, Biological Evaluation, and Pharmacokinetics of the Human Anti-HER1 Monoclonal Antibody Panitumumab Labeled with 86Y for Quantitative PET of Carcinoma , 2010, Journal of Nuclear Medicine.

[6]  Anna M Wu,et al.  Antibody vectors for imaging. , 2010, Seminars in nuclear medicine.

[7]  Michael V. Green,et al.  MONICA: a compact, portable dual gamma camera system for mouse whole-body imaging. , 2010, Nuclear Medicine and Biology.

[8]  H. Kahu,et al.  Repeated Intraperitoneal α-Radioimmunotherapy of Ovarian Cancer in Mice , 2009, Journal of oncology.

[9]  T. Nayak,et al.  PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A″-DTPA-cetuximab , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  M. Brechbiel,et al.  Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent , 2009, British journal of pharmacology.

[11]  Q. Le,et al.  PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models , 2009, Journal of Nuclear Medicine.

[12]  Anna M. Wu,et al.  Antibodies and Antimatter: The Resurgence of Immuno-PET , 2008, Journal of Nuclear Medicine.

[13]  M. Brechbiel,et al.  Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. , 2008, Cancer biotherapy & radiopharmaceuticals.

[14]  V. Tolmachev.  Imaging of HER-2 overexpression in tumors for guiding therapy. , 2008, Current pharmaceutical design.

[15]  A. Bhattacharya.  Immunoglobulins: Structure and Function , 2008 .

[16]  P. Choyke,et al.  Design, synthesis, and characterization of a dual modality positron emission tomography and fluorescence imaging agent for monoclonal antibody tumor-targeted imaging. , 2007, Journal of medicinal chemistry.

[17]  P. Keegan,et al.  FDA drug approval summary: panitumumab (Vectibix). , 2007, The oncologist.

[18]  G. Slegers,et al.  Biodistribution and planar gamma camera imaging of (123)I- and (131)I-labeled F(ab')(2) and Fab fragments of monoclonal antibody 14C5 in nude mice bearing an A549 lung tumor. , 2007, Nuclear medicine and biology.

[19]  L L Houston,et al.  Avidity-Mediated Enhancement of In vivo Tumor Targeting by Single-Chain Fv Dimers , 2006, Clinical Cancer Research.

[20]  M. Tabrizi,et al.  Elimination mechanisms of therapeutic monoclonal antibodies. , 2006, Drug discovery today.

[21]  S. Ametamey,et al.  In vivo Evaluation of 177Lu- and 67/64Cu-Labeled Recombinant Fragments of Antibody chCE7 for Radioimmunotherapy and PET Imaging of L1-CAM-Positive Tumors , 2005, Clinical Cancer Research.

[22]  David J. Yang,et al.  Radiation dosimetry of 99mTc-labeled C225 in patients with squamous cell carcinoma of the head and neck. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[23]  R. Figlin,et al.  Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Chappell,et al.  Radioimmunotherapy of human colon carcinoma xenografts using a 213Bi-labeled domain-deleted humanized monoclonal antibody. , 2004, Cancer biotherapy & radiopharmaceuticals.

[25]  Neal Rosen,et al.  Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors , 2004, Nature Biotechnology.

[26]  D. Bigner,et al.  Human/murine chimeric 81C6 F(ab')(2) fragment: preclinical evaluation of a potential construct for the targeted radiotherapy of malignant glioma. , 2004, Nuclear medicine and biology.

[27]  K. Britton.  The development of new radiopharmaceuticals , 2004, European Journal of Nuclear Medicine.

[28]  M. Brechbiel,et al.  A new and convenient method for purification of 86Y using a Sr(II) selective resin and comparison of biodistribution of 86Y and 111In labeled Herceptin. , 2002, Nuclear medicine and biology.

[29]  L. Chappell,et al.  In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications. , 2002, Nuclear medicine and biology.

[30]  L. Khawli,et al.  Stable, genetically engineered F(ab')(2) fragments of chimeric TNT-3 expressed in mammalian cells. , 2002, Hybridoma and hybridomics.

[31]  R. Ober,et al.  Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. , 2001, International immunology.

[32]  S. Batra,et al.  99mTc-labeled divalent and tetravalent CC49 single-chain Fv's: novel imaging agents for rapid in vivo localization of human colon carcinoma. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  G. Adams,et al.  High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. , 2001, Cancer research.

[34]  S. Mirzadeh,et al.  In vivo evaluation of bismuth-labeled monoclonal antibody comparing DTPA-derived bifunctional chelates. , 2001, Cancer biotherapy & radiopharmaceuticals.

[35]  C. Davis,et al.  Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy. , 2001, Critical reviews in oncology/hematology.

[36]  D. Milenic.  Radioimmunotherapy: designer molecules to potentiate effective therapy. , 2000, Seminars in radiation oncology.

[37]  I. Pastan,et al.  Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. , 1997, Bioorganic & medicinal chemistry.

[38]  T. Yokota,et al.  Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. , 1993, Cancer research.

[39]  M. Brechbiel,et al.  Spectrophotometric method for the determination of a bifunctional DTPA ligand in DTPA-monoclonal antibody conjugates. , 1992, Bioconjugate chemistry.

[40]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[41]  C. Heusser,et al.  Different behaviour of mouse‐human chimeric antibody F(ab')2 fragments of IgG1, IgG2 and IgG4 sub‐class in vivo , 1992, International journal of cancer.

[42]  T. Yokota,et al.  Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. , 1991, Cancer research.

[43]  S. Larson,et al.  Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. , 1991, Journal of the National Cancer Institute.

[44]  D. Milenic,et al.  Characterization of Primate Antibody Responses to Administered Murine Monoclonal Immunoglobulin , 1990, The International journal of biological markers.

[45]  D. Milenic,et al.  Comparison of methods for the generation of immunoreactive fragments of a monoclonal antibody (B72.3) reactive with human carcinomas. , 1989, Journal of immunological methods.

[46]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.

[47]  J N Weinstein,et al.  Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice. , 1986, Cancer research.

[48]  F. Buchegger,et al.  Detection of colorectal carcinoma by emission-computerized tomography after injection of 123I-labeled Fab or F(ab')2 fragments from monoclonal anti-carcinoembryonic antigen antibodies. , 1986, The Journal of clinical investigation.

[49]  R. Wahl,et al.  Improved radioimaging and tumor localization with monoclonal F(ab')2. , 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[50]  J. Schlom,et al.  Radiolocalization of human mammary tumors in athymic mice by a monoclonal antibody. , 1983, Cancer research.

[51]  E. Kim,et al.  Circulating immune complexes in cancer patients receiving goat radiolocalizing antibodies to carcinoembryonic antigen. , 1980, Cancer research.

[52]  P. Fraker,et al.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril. , 1978, Biochemical and biophysical research communications.

[53]  A. Nisonoff,et al.  Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds. , 1960, Archives of biochemistry and biophysics.

[54]  O. H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.